Granting Stock Options to Directors, Corporate Auditors and Executive Officers
First written in FY2017-Q2. 12 of 21 entries say "Advanced", first in FY2018-Q2. Latest entry: 2026-09-01.
- FY2026Expanded stock compensation eligibility to managers across all Group companiesAnnual report
「We have introduced a stock compensation program (restricted stock) under which part of the compensation is paid in shares of the Company to managers across all Group companies.」
Expanded eligibility from stock options and restricted stock compensation for directors, executive officers and others to a stock compensation program for managers across all Group companies. - FY2026-H1AdvancedAnnual report
「At a Board of Directors meeting held on 24 June 2025, the company resolved to dispose of treasury shares as restricted stock compensation and disposed of 544,888 treasury shares during the current interim consolidated accounting period. As a result, treasury shares decreased by ¥124 million and capital surplus increased by ¥32 million.」
Disposed of 544,888 treasury shares as restricted stock compensation for directors and other officers, advancing the implementation of the stock compensation program. - FY2024AdvancedAnnual report
「During the consolidated fiscal year, the total number of shares outstanding increased by 340,996. This comprised an increase of 86,600 shares through the exercise of stock acquisition rights and an increase of 254,396 shares through the issuance of new shares as specified restricted stock, or restricted stock compensation.」
Regarding stock-based compensation for directors, executive officers and others, 254,396 restricted stock shares were issued and stock acquisition rights representing 86,600 shares were exercised. - FY2024-Q3Increase in Shares Through Exercise of Stock Acquisition RightsAnnual report
「1 October 2023–31 December 2023 (Note) 33 33,786 3 2,626 3 1,198 (Note) The increase resulted from the exercise of stock acquisition rights.」
From October through December 2023, the total number of shares outstanding increased by 33 thousand through the exercise of stock acquisition rights, while capital stock and capital surplus each increased by ¥3 million. - FY2024-Q2Share issuance during the quarterAnnual report
「1 July 2023–30 September 2023 (Note) 278 33,752 19 2,623 19 1,195 (Note) The increases resulted from the exercise of stock acquisition rights and the issuance of new shares as restricted stock compensation.」
From July through September 2023, the total number of shares outstanding increased by 278 thousand, while capital stock and capital surplus each increased by ¥19 million. The stated reasons were the exercise of stock acquisition rights and the issuance of new shares as restricted stock compensation. - FY2023-Q2AdvancedAnnual report
「Of the shares outstanding as of the filing date, 265,466 were issued as restricted stock compensation through an in-kind contribution, with total monetary compensation receivables of ¥32 million used as the contribution.」
The company disclosed 265,466 shares issued as restricted stock compensation and total monetary compensation receivables of ¥32 million, an increase from the 231,954 shares disclosed previously. - FY2023-Q1Increase in Shares Through Exercise of Stock Acquisition RightsAnnual report
「1 April 2022–30 June 2022 (Note) 33 33,170 2 2,584 2 1,156 (Note) The increase resulted from the exercise of stock acquisition rights.」
The total number of shares outstanding increased by 33 thousand during the quarter through the exercise of stock acquisition rights, bringing shares outstanding as of the filing date to 33,195,120. - FY2022-Q2AdvancedAnnual report
「Of the shares outstanding as of the filing date, 231,954 were issued as restricted stock compensation through an in-kind contribution, with total monetary compensation receivables of ¥33 million used as the contribution.」
The company disclosed the issuance of 231,954 shares as restricted stock compensation for directors and others, adding specific issuance results to the compensation system disclosed previously. - FY2021AdvancedAnnual report
「Pursuant to a resolution of the Board of Directors held on 23 June 2020, the company issued new shares as restricted stock compensation on 8 July 2020. As a result, the number of shares increased by 210,566, bringing the total number of shares outstanding to 32,848,066.」
The compensation system for directors and others has shifted from disclosure centered on stock acquisition rights to restricted stock compensation, and 210,566 shares were issued. Under the new compensation policy, base compensation, performance-based compensation and stock-based compensation are targeted at 70%, 20% and 10%, respectively. - FY2021-Q1ReframedAnnual report
「Pursuant to a resolution of the Board of Directors held on 23 June 2020, the company issued new shares as restricted stock compensation on 8 July 2020. As a result, the number of shares increased by 210,566, bringing the total number of shares outstanding to 32,848,066.」
The disclosure describes the issuance of new shares as restricted stock compensation, in addition to the grant of stock acquisition rights, as compensation using shares for directors and others. The number of shares increased by 210,566 on 8 July 2020. - FY2020-Q3Increase in shares outstanding through the exercise of stock acquisition rightsAnnual report
「Between 1 January 2020 and 31 January 2020, the total number of shares outstanding increased by 15,000 through the exercise of stock acquisition rights.」
The total number of shares outstanding increased by 15,000 in January 2020 through the exercise of stock acquisition rights. - FY2020-Q2AdvancedAnnual report
「Resolution date 21 June 2019 Categories and number of grantees Company directors (excluding outside directors and directors who are Audit & Supervisory Committee members): 7 Company executive officers: 4 Directors of subsidiaries (excluding outside directors): 54 Number of stock acquisition rights* 2,468 Class, details and number of shares underlying stock acquisition rights* Common shares: 246,800 shares」
Under the resolution dated 21 June 2019, the company granted 2,468 stock acquisition rights representing 246,800 underlying shares to company directors, executive officers and subsidiary directors. - FY2019AdvancedAnnual report
「The decrease in Series 1 stock acquisition rights resulted from their exercise. The increase in Series 3 stock acquisition rights resulted from their issuance.」
6,200 shares were acquired through the exercise of Series 1 stock acquisition rights, and Series 3 stock acquisition rights representing 154,000 shares were issued. - FY2019-Q2AdvancedAnnual report
「Resolution date 22 June 2018 Categories and number of grantees Company directors (excluding outside directors and directors who are Audit & Supervisory Committee members): 7 Company executive officers: 3 Directors of subsidiaries (excluding outside directors): 49 Number of stock acquisition rights* 1,540 Class, details and number of shares underlying stock acquisition rights* Common shares: 154,000 shares」
Under the resolution dated 22 June 2018, the company granted 1,540 stock acquisition rights representing 154,000 underlying shares to company directors, executive officers and subsidiary directors. - FY2018-Q2AdvancedAnnual report
「The company issued stock acquisition rights during the second quarter accounting period. Number of stock acquisition rights 1,174 (Note) 1 Number of underlying shares 117,400 (Note) 1」
During the quarter, the company issued 1,174 stock acquisition rights representing 117,400 underlying shares to directors, audit & supervisory board members, executive officers and others. - FY2017RestatedAnnual report
「Number of stock acquisition rights: 1,027; number of underlying shares: 102,700; exercise period for stock acquisition rights: 16 September 2016 to 15 September 2046」
The company disclosed 102,700 remaining shares at fiscal year-end under stock acquisition rights in the form of stock-based compensation for directors, executive officers and others. - FY2017-Q2First statedAnnual report
「The company issued stock acquisition rights during the second quarter accounting period.」
The company issued 1,037 stock acquisition rights representing 103,700 underlying shares. The exercise period runs from 16 September 2016 to 15 September 2046, and the basic condition is that they may be exercised after the holders, including directors, audit & supervisory board members and executive officers of the company and its subsidiaries, cease to hold those positions.